FDA authorizes expanded access program for investigational pancreatic cancer drug daraxonrasib
The Facts
- The FDA issued a "safe to proceed" letter allowing Revolution Medicines to initiate an expanded access treatment protocol for daraxonrasib.
- The expanded access program is for patients with previously treated metastatic pancreatic ductal adenocarcinoma.
- Daraxonrasib is an investigational drug that has not yet been approved for general use.
- Before this authorization, patients could receive daraxonrasib only through clinical trials, where available slots were limited relative to demand.
- Expanded access is a regulatory pathway that can allow patients with serious or life-threatening conditions to receive investigational treatments outside clinical trials before approval.
- The FDA said it received Revolution Medicines' expanded access request on April 28 and signed it on April 30.
- Reports on the authorization said it was not yet clear how soon eligible patients would actually be able to begin receiving daraxonrasib through the program.
Context
Who can seek daraxonrasib under this program?
The FDA said the program is for patients with previously treated metastatic pancreatic ductal adenocarcinoma, meaning pancreatic cancer that has spread and has already been treated with other therapies U.S. Food and Drug …,U.S. News & World R….
What does expanded access mean here?
Expanded access is an FDA pathway that can let patients with serious or life-threatening illnesses receive investigational drugs outside clinical trials before the drugs are approved, under a monitored treatment protocol U.S. Food and Drug …,Medscape,Drugs.com.
What is still unresolved after the FDA decision?
The authorization allows Revolution Medicines to open the program, but reports said it was not immediately clear when eligible patients would actually start receiving the drug Morningstar,Boston Globe.
How left and right read it
For patients with previously treated metastatic pancreatic ductal adenocarcinoma, this matters because an investigational drug that had been limited to oversubscribed clinical trials may now become available through expanded access. The important point is that a pathway meant for serious or life-threatening conditions could widen access for people who had few ways to seek this treatment before approval.
The notable part here is that the FDA used an existing regulatory pathway to allow access to an investigational drug before general approval, and it acted quickly after receiving the company's request. At the same time, authorization is not the same as treatment in hand, since reports said it was still unclear how soon eligible patients would actually begin receiving daraxonrasib through the program.
The receipts — all 18 sources
Wire services (2)
Independent coverage (16)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.